false
0000907654
0000907654
2024-08-16
2024-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 16, 2024
ARCA biopharma, Inc.
(Exact
name of Registrant as Specified in Its Charter)
| Delaware |
|
000-22873 |
|
36-3855489 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
10170 Church Ranch Way
Suite 100 |
|
|
| Westminster, Colorado |
|
80021 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s
Telephone Number, Including Area Code: (720) 940-2100
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☒ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common |
|
ABIO |
|
The Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
As
previously disclosed, on April 3, 2024, ARCA biopharma, Inc., a Delaware corporation (“ARCA”), entered into an Agreement
and Plan of Merger and Reorganization (the “Merger Agreement”) pursuant to which, among other matters, and subject
to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation and
wholly owned subsidiary of ARCA (“First Merger Sub”), will merge with and into Oruka Therapeutics, Inc. (“Oruka”),
with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the “First Merger”),
and Oruka will merge with and into Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of
ARCA (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), with Second Merger
Sub being the surviving entity of the merger (the “Second Merger” and, together with the First Merger, the “Merger”).
On
August 16, 2024, ARCA issued a press release announcing that its Board of Directors has declared a special cash dividend to its stockholders
in connection with the Merger (the “Special Dividend”). The Special Dividend, which ARCA estimates to be $1.59 per
share of ARCA’s common stock, will be payable in cash to the stockholders of record as of August 26, 2024. The exact amount of
the Special Dividend will be calculated pursuant to the Merger Agreement and based on ARCA’s reasonable, good faith approximation
of the amount by which ARCA’s net cash, as determined prior to the closing of the Merger, will
exceed $5,000,000. Total actual distribution of the amount of the Special Dividend could be higher or lower than $1.59 per share and
the estimate for amount to be distributed to stockholders could change. The payment date in respect of the Special Dividend is scheduled
for August 28, 2024.
Payment of the Special Dividend is conditioned upon the approval of the
Merger by ARCA’s stockholders which ARCA’s stockholders will consider and vote upon at the special meeting of ARCA stockholders
scheduled for 9:00 a.m. MT on August 22, 2024. Closing of the Merger is expected to occur on August 29, 2024 assuming that the transaction
is approved by ARCA’s stockholders and the satisfaction or waiver of all conditions under the Merger Agreement.
A
copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Forward-Looking
Statements
This
Current Report on Form 8-K and the exhibits filed or furnished herewith contain forward-looking statements (including
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended) concerning ARCA, Oruka, the proposed transactions and other matters. These forward-looking statements
include express or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company’s
listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected
executive officers and directors of the combined company; each company’s and the combined company’s expected cash position
at the closing of the proposed Merger (including completion of Oruka’s private placement) and cash runway of the combined company;
the expected contribution and payment of dividends in connection with the Merger, including the timing thereof; the future operations
of the combined company; the nature, strategy and focus of the combined company; the development and commercial potential and potential
benefits of any product candidates of the combined company; anticipated preclinical and clinical drug development activities and related
timelines, including the expected timing for data and other clinical results; the combined company having sufficient resources to advance
its pipeline candidates; and other statements that are not historical fact. The words “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “will,” “would” and similar expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting ARCA, Oruka, including the pre-closing private financing, or the Merger
will be those that have been anticipated.
The
forward-looking statements contained in this communication are based on current expectations and beliefs concerning future developments
and their potential effects and therefore subject to other risks and uncertainties. These risks and uncertainties include, but are not
limited to, risks associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger, including
ARCA’s failure to obtain stockholder approval for the Merger, risks associated with the potential failure to complete the financing
transaction in a timely manner or at all, risks associated with the uncertainty as to the timing of the consummation of the Merger and
the ability of each of ARCA and Oruka to consummate the transactions contemplated by the Merger, risks associated with ARCA’s continued
listing on Nasdaq until closing of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental
entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise
to the termination of the Merger prior to the closing or consummation of the Merger, risks associated with the possible failure to realize
certain anticipated benefits of the Merger, including with respect to future financial and operating results; the effect of the completion
of the Merger on the combined company’s business relationships, operating results and business generally; risks associated with
the combined company’s ability to manage expenses and unanticipated spending and costs that could reduce the combined company’s
cash resources; risks related to the combined company’s ability to correctly estimate its operating expenses and other events;
changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital
to continue to advance its product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted
against the combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby;
the ability of the combined company to obtain, maintain and protect its intellectual property rights, in particular those related to
its product candidates; the combined company’s ability to advance the development of its product candidates or preclinical activities
under the timelines it anticipates in planned and future clinical trials; the combined company’s ability to replicate in later
clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; the combined
company’s ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing
programs or other collaborations; regulatory requirements or developments and the combined company’s ability to obtain necessary
approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory
pathways; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses
resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger;
legislative, regulatory, political and economic developments; and those risks and uncertainties and other factors more fully described
in filings with the Securities and Exchange Commission (“SEC”), including reports filed on Form 10-K, 10-Q and 8-K,
in other filings that ARCA makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement/Prospectus
described below under “Important Additional Information About the Proposed Transaction Filed with the SEC,” and in other
filings made by ARCA with the SEC from time to time and available at www.sec.gov. These forward-looking statements are based on current
expectations, and with regard to the proposed transaction, are based on ARCA’s current expectations, estimates and projections
about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s
beliefs and certain assumptions made by ARCA, all of which are subject to change. Such forward-looking statements are made as of the
date of this release, and the parties undertake no obligation to update such statements to reflect subsequent events or circumstances,
except as otherwise required by securities and other applicable law.
No
Offer or Solicitation
This
Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended to and do not constitute (i) a solicitation
of a proxy, consent or approval with respect to any securities or in respect of the proposed transactions (the “Proposed Transactions”)
between ARCA and Oruka or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase
or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer
of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus
meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved
by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any
jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or
instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce,
or any facility of a national securities exchange, of any such jurisdiction.
NEITHER
THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM
8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE.
Important
Additional Information About the Proposed Transaction Filed with the SEC
This
Current Report on Form 8-K and the exhibits filed or furnished herewith are not substitutes for the registration statement on Form S-4
or for any other document that ARCA has filed or may file with the SEC in connection with the Proposed Transactions. In connection with
the Proposed Transactions, ARCA has filed with the SEC a registration statement on Form S-4, which contains a proxy statement/prospectus
of ARCA. ARCA URGES INVESTORS AND STOCKHOLDERS TO READ THE REGISTRATION STATEMENT ON FORM S-4, PROXY STATEMENT/PROSPECTUS AND ANY OTHER
RELEVANT DOCUMENTS THAT ARE OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND
IN THEIR ENTIRETY, BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCA, ORUKA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.
Investors and stockholders can obtain free copies of the proxy statement/prospectus and other documents filed by ARCA with the SEC through
the website maintained by the SEC at www.sec.gov. Stockholders are urged to read the proxy statement/prospectus and the other relevant
materials filed with the SEC before making any voting or investment decision with respect to the Proposed Transactions. In addition,
investors and stockholders should note that ARCA communicates with investors and the public using its website (https://arcabio.com/investors/).
Participants
in the Solicitation
ARCA,
Oruka and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders
in connection with the Proposed Transactions. Information about ARCA’s directors and executive officers including a description
of their interests in ARCA is included in the proxy statement/prospectus relating to the Proposed Transactions and ARCA’s most
recent Annual Report on Form 10-K, including any information incorporated therein by reference, each as filed with the SEC.
Information about ARCA’s and Oruka’s respective directors and executive officers and their interests in the Proposed Transactions
is included in the proxy statement/prospectus relating to the Proposed Transactions filed with the SEC.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
ARCA biopharma, Inc.
(Registrant) |
| |
|
|
| Date: August 16, 2024 |
By: |
/s/ C. Jeffrey Dekker |
| |
|
Name: |
C. Jeffrey Dekker |
| |
|
Title: |
Chief Financial Officer |
4
Exhibit 99.1
ARCA biopharma Declares Special Dividend in
Connection with the Proposed Merger with Oruka Therapeutics
Special dividend estimated to be $1.59 per
share
Payment of special dividend conditioned upon
ARCA stockholder approval of the Proposed Merger with Oruka
Westminster, CO, August 16, 2024 – ARCA biopharma,
Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors has declared a special cash dividend (the “Special
Dividend”) in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”)
pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”).
The Special Dividend, which ARCA estimates will be $1.59 per share
of ARCA’s common stock, will be payable in cash to the stockholders of record as of August 26, 2024. The exact amount of the Special
Dividend will be calculated pursuant to the Merger Agreement and based on ARCA’s reasonable, good faith approximation of the amount
by which ARCA’s net cash, as determined prior to the closing of the Merger, will exceed $5,000,000.
Total actual distribution of the amount of the Special Dividend could be higher or lower than $1.59 per share and the estimate for amount
to be distributed to stockholders could change. The payment date in respect of the Special Dividend is scheduled for August 28, 2024.
Payment of the Special Dividend is conditioned upon approval by the
ARCA stockholders of the Merger, which ARCA’s stockholders will consider and vote upon at the special meeting of ARCA stockholders
scheduled for 9:00 a.m. MT on August 22, 2024. Closing of the Merger is expected to occur on August 29, 2024 assuming
that the transaction is approved by ARCA’s stockholders and the satisfaction or waiver of all conditions under the Merger Agreement.
If you need assistance in voting your shares
or have questions regarding the special meeting of ARCA’s stockholders, please contact ARCA’s proxy solicitor, Innisfree
M&A Incorporated at (877) 750-8310 (toll-free).
About ARCA biopharma
ARCA biopharma is dedicated to developing
genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. For more
information, please visit www.arcabio.com or follow the company on LinkedIn.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics
designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from
chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease
clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies
that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory
diseases. For more information, visit www.orukatx.com.
Forward-Looking Statements
This communication contains forward-looking
statements (including within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act) concerning
ARCA, Oruka, the proposed transactions and other matters. These forward-looking statements include express or implied statements relating
to the structure, timing and completion of the proposed Merger; the combined company’s listing on Nasdaq after closing of the proposed
Merger; expectations regarding the ownership structure of the combined company; the expected executive officers and directors of the
combined company; each company’s and the combined company’s expected cash position at the closing of the proposed Merger
(including completion of Oruka’s private placement) and cash runway of the combined company; the expected contribution and payment
of dividends in connection with the Merger, including the timing thereof; the future operations of the combined company; the nature,
strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates
of the combined company; anticipated preclinical and clinical drug development activities and related timelines, including the expected
timing for data and other clinical results; the combined company having sufficient resources to advance its pipeline candidates; and
other statements that are not historical fact. The words “anticipate,” “believe,” “contemplate,”
“continue,” “could,” “estimate,” “expect,” “intends,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “will,” “would” and similar expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting ARCA, Oruka, including the pre-closing private financing, or the Merger
will be those that have been anticipated.
The forward-looking statements contained
in this communication are based on current expectations and beliefs concerning future developments and their potential effects and therefore
subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks associated with the possible
failure to satisfy the conditions to the closing or consummation of the Merger, including ARCA’s failure to obtain stockholder
approval for the Merger, risks associated with the potential failure to complete the financing transaction in a timely manner or at all,
risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability of each of ARCA and Oruka to
consummate the transactions contemplated by the Merger, risks associated with ARCA’s continued listing on Nasdaq until closing
of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate
the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger
prior to the closing or consummation of the Merger, risks associated with the possible failure to realize certain anticipated benefits
of the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on the combined
company’s business relationships, operating results and business generally; risks associated with the combined company’s
ability to manage expenses and unanticipated spending and costs that could reduce the combined company’s cash resources; risks
related to the combined company’s ability to correctly estimate its operating expenses and other events; changes in capital resource
requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its
product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company
or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby; the ability of the combined
company to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; the
combined company’s ability to advance the development of its product candidates or preclinical activities under the timelines it
anticipates in planned and future clinical trials; the combined company’s ability to replicate in later clinical trials positive
results found in preclinical studies and early-stage clinical trials of its product candidates; the combined company’s ability
to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations;
regulatory requirements or developments and the combined company’s ability to obtain necessary approvals from the U.S. Food and
Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses
to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential
adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political
and economic developments; and those risks and uncertainties and other factors more fully described in filings with the Securities and
Exchange Commission (“SEC”), including reports filed on Form 10-K, 10-Q and 8-K, in other
filings that ARCA makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement/Prospectus
described below under “Important Additional Information About the Proposed Transaction Filed with the SEC,” and in other
filings made by ARCA with the SEC from time to time and available at www.sec.gov. These forward-looking statements are based on current
expectations, and with regard to the proposed transaction, are based on ARCA’s current expectations, estimates and projections
about the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s
beliefs and certain assumptions made by ARCA, all of which are subject to change. Such forward-looking statements are made as of the
date of this release, and the parties undertake no obligation to update such statements to reflect subsequent events or circumstances,
except as otherwise required by securities and other applicable law.
No Offer or Solicitation
This communication is not intended to and
do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed
transactions (the “Proposed Transactions”) between ARCA and Oruka or (ii) an offer to sell or the solicitation
of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions
or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended,
or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained,
the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of
the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission,
telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
NEITHER THE SEC NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.
Important Additional Information About
the Proposed Transaction Filed with the SEC
This communication is not a substitute for
the registration statement on Form S-4 or for any other document that ARCA has filed or may file with the SEC in connection with the
Proposed Transactions. In connection with the Proposed Transactions, ARCA has filed with the SEC a registration statement on Form S-4, which
contains a proxy statement/prospectus of ARCA. ARCA URGES INVESTORS AND STOCKHOLDERS TO READ THE REGISTRATION STATEMENT ON FORM S-4,
PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS
TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCA, ORUKA, THE PROPOSED
TRANSACTIONS AND RELATED MATTERS. Investors and stockholders can obtain free copies of the proxy statement/prospectus and other documents
filed by ARCA with the SEC through the website maintained by the SEC at www.sec.gov. Stockholders are urged to read the proxy statement/prospectus
and the other relevant materials filed with the SEC before making any voting or investment decision with respect to the Proposed Transactions.
In addition, investors and stockholders should note that ARCA communicates with investors and the public using its website (https://arcabio.com/investors/).
Participants in the Solicitation
ARCA, Oruka and their respective directors
and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the Proposed
Transactions. Information about ARCA’s directors and executive officers including a description of their interests in ARCA is included
in the proxy statement/prospectus relating to the Proposed Transactions and ARCA’s most recent Annual Report on Form 10-K, including
any information incorporated therein by reference, each as filed with the SEC. Information about ARCA’s and Oruka’s respective
directors and executive officers and their interests in the Proposed Transactions is included in the proxy statement/prospectus relating
to the Proposed Transactions filed with the SEC.
ARCA biopharma Investor & Media Contact:
Jeff Dekker
720.940.2122
ir@arcabio.com
Oruka Therapeutics Investor Relations Contact:
Alan Lada
650.606.7911
Alan.lada@orukatx.com
v3.24.2.u1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
ARCA Biopharma (NASDAQ:ABIO)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
ARCA Biopharma (NASDAQ:ABIO)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
